| 5.35 -0.06 (-1.11%) | 11-07 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |  |
|||
| Targets | 6-month : | 7.08 |
1-year : | 7.73 |
| Resists | First : | 6.06 |
Second : | 6.62 |
| Pivot price | 5.88 |
|||
| Supports | First : | 5.17 |
Second : | 4.3 |
| MAs | MA(5) : | 5.58 |
MA(20) : | 5.93 |
| MA(100) : | 6.35 |
MA(250) : | 6.89 |
|
| MACD | MACD : | -0.2 |
Signal : | -0.1 |
| %K %D | K(14,3) : | 6.1  |
D(3) : | 10.7 |
| RSI | RSI(14): 36.6 |
|||
| 52-week | High : | 11.22 | Low : | 4.34 |
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and BEARISH in mid-long term.[ AURA ] has closed above bottom band by 6.0%. Bollinger Bands are 53.3% wider than normal. The large width of the bands suggest high volatility as compared to its normal range. The bands have been in this wide range for 0 days. This is a sign that the current trend might continue.
| If tomorrow: | Open lower | Open higher |
| High: | 5.42 - 5.47 | 5.47 - 5.5 |
| Low: | 5.06 - 5.13 | 5.13 - 5.17 |
| Close: | 5.27 - 5.38 | 5.38 - 5.45 |
Aura Biosciences, Inc. operates as a biotechnology company that develops therapies to treat cancer. The company develops virus-like drug conjugates (VDC) technology platform for the treat tumors of high unmet need in ocular and urologic oncology. It develops AU-011, a VDC candidate for the treatment of primary choroidal melanoma. It also develops AU-011 in additional ocular oncology indications, including choroidal metastases. The company was incorporated in 2009 and is headquartered in Cambridge, Massachusetts.
Sat, 08 Nov 2025
Aura Biosciences Inc. stock trend forecast - Market Performance Recap & Fast Gaining Stock Strategy Reports - newser.com
Fri, 07 Nov 2025
How Aura Biosciences Inc. stock performs after earnings - New Guidance & Breakout Confirmation Trade Signals - newser.com
Thu, 06 Nov 2025
Can you recover from losses in Aura Biosciences Inc. - Market Performance Summary & AI Powered Market Entry Ideas - newser.com
Thu, 06 Nov 2025
Why Aura Biosciences Inc. stock appeals to dividend seekers - 2025 Historical Comparison & Expert Verified Movement Alerts - fcp.pa.gov.br
Wed, 29 Oct 2025
Aura Biosciences CEO Makes Significant Stock Sale! - TipRanks
Thu, 16 Oct 2025
Aura Biosciences CTO Makes a Bold Move with Stock Sale! - TipRanks
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Neutral |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 62 (M) |
| Shares Float | 35 (M) |
| Held by Insiders | 1.9 (%) |
| Held by Institutions | 84.6 (%) |
| Shares Short | 3,140 (K) |
| Shares Short P.Month | 2,920 (K) |
| EPS | -1.96 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 2.8 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | -32.2 % |
| Return on Equity (ttm) | -55.4 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | -1.74 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -83 (M) |
| Levered Free Cash Flow | -49 (M) |
| PE Ratio | -2.75 |
| PEG Ratio | 0 |
| Price to Book value | 1.9 |
| Price to Sales | 0 |
| Price to Cash Flow | -3.99 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|